Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Net Income towards Common Stockholders (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Net Income towards Common Stockholders for 11 consecutive years, with -$5.9 million as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders rose 6.56% to -$5.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$27.6 million through Dec 2025, down 142.11% year-over-year, with the annual reading at -$27.5 million for FY2025, 14.12% down from the prior year.
  • Net Income towards Common Stockholders hit -$5.9 million in Q4 2025 for Aptevo Therapeutics, up from -$9.0 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $946000.0 in Q1 2023 to a low of -$9.0 million in Q3 2025.
  • Historically, Net Income towards Common Stockholders has averaged -$2.2 million across 5 years, with a median of $140500.0 in 2021.
  • Biggest five-year swings in Net Income towards Common Stockholders: surged 431.46% in 2023 and later tumbled 2254.27% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at $325000.0 in 2021, then surged by 60.31% to $521000.0 in 2022, then plummeted by 43.76% to $293000.0 in 2023, then crashed by 2254.27% to -$6.3 million in 2024, then rose by 6.56% to -$5.9 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for APVO at -$5.9 million in Q4 2025, -$9.0 million in Q3 2025, and -$6.2 million in Q2 2025.